Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer
SPECIFIC STUDY AIMS Specific Aim 1: To use gene expression analysis of primary cervical cancers to identify a gene expression signature that predicts for lymph node metastases in this disease. Specific Aim 2: To predict lymph node metastases by performing multiplex measurements of cancer-associated proteins and cytokines using proximity ligation assay (PLA) on plasma samples. Specific Aim 3: To measure circulating human papilloma virus (HPV) DNA in the plasma samples of cervical cancer patients using real-time quantitative polymerase chain reaction (qPCR) and determine its ability to predict for nodal metastases. Specific Aim 4: To use deep sequencing to evaluate gene and sequence differences between cervical cancer patients with and without lymph node metastasis.
- other : Blood draw
Ages Eligible For Study:
- Patients must have a known or suspected cervical cancer. - Age >18 years. - Patients must have no other active cancer at the time of diagnosis. - Patients must have no history of a hysterectomy. - Patients must be able to give informed consent. - Patients must be willing to have undergone a standard-of-care biopsy of the cervical tumor to provide tissue for the study. - Patients must be willing to give a blood sample to provide plasma for the study. - Patients must have completed a standard-of-care FDG-PET/CT prior to initiation of therapy, for assessment of lymph nodes. - Patients must be pre-treatment.